Cargando…
Local treatment of a pleural mesothelioma tumor with ONCOS-102 induces a systemic antitumor CD8(+) T-cell response, prominent infiltration of CD8(+) lymphocytes and Th1 type polarization
Late stage cancer is often associated with reduced immune recognition and a highly immunosuppressive tumor microenvironment. The presence of tumor infiltrating lymphocytes (TILs) and specific gene-signatures prior to treatment are linked to good prognosis, while the opposite is true for extensive im...
Autores principales: | Ranki, Tuuli, Joensuu, Timo, Jäger, Elke, Karbach, Julia, Wahle, Claudia, Kairemo, Kalevi, Alanko, Tuomo, Partanen, Kaarina, Turkki, Riku, Linder, Nina, Lundin, Johan, Ristimäki, Ari, Kankainen, Matti, Hemminki, Akseli, Backman, Charlotta, Dienel, Kasper, von Euler, Mikael, Haavisto, Elina, Hakonen, Tiina, Juhila, Juuso, Jaderberg, Magnus, Priha, Petri, Vassilev, Lotta, Vuolanto, Antti, Pesonen, Sari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4292415/ https://www.ncbi.nlm.nih.gov/pubmed/25941579 http://dx.doi.org/10.4161/21624011.2014.958937 |
Ejemplares similares
-
Repeated intratumoral administration of ONCOS-102 leads to systemic antitumor CD8(+) T-cell response and robust cellular and transcriptional immune activation at tumor site in a patient with ovarian cancer
por: Vassilev, L, et al.
Publicado: (2015) -
Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers
por: Ranki, Tuuli, et al.
Publicado: (2016) -
Local immunotherapy with ONCOS-102 shapes harmful tumor associated CD68+ macrophages to become beneficial cells that correlate with increased overall survival
por: Pesonen, Sari, et al.
Publicado: (2015) -
Gene expression analysis of tumors demonstrates an induction of Th1 type immune response following intratumoral administration of ONCOS-102 in refractory solid tumor patients
por: Majumder, Mamun, et al.
Publicado: (2014) -
Immunological data from cancer patients treated with Ad5/3-E2F-Δ24-GMCSF suggests utility for tumor immunotherapy
por: Hemminki, Otto, et al.
Publicado: (2015)